| Date Filed | Type | Description |
| 08/11/2022 |
SC 13D/A
| Abingworth LLP reports a 4.4% stake in Verona Pharma plc |
| 07/11/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 05/13/2022 |
SC 13G
| Abingworth LLP reports a 5.5% stake in HILLEVAX, INC. |
| 04/08/2022 |
SC 13D/A
| Abingworth LLP reports a 15.3% stake in Soleno Therapeutics Inc. |
| 04/07/2022 |
SC 13D/A
| Abingworth LLP reports a 11.1% stake in Vera Therapeutics, Inc. |
| 03/21/2022 |
SC 13D/A
| Abingworth LLP reports a 8.9% stake in Sierra Oncology, Inc. |
| 02/25/2022 |
SC 13D/A
| Abingworth LLP reports a 6.5% stake in Exicure, Inc. |
| 02/14/2022 |
SC 13G/A
| Abingworth LLP reports a 7.9% stake in VAXCYTE, INC. |
| 02/10/2022 |
SC 13D/A
| Abingworth LLP reports a 11.3% stake in Sierra Oncology, Inc. |
| 11/05/2021 |
SC 13D/A
| Abingworth LLP reports a 12.6% stake in Sierra Oncology, Inc. |
| 10/04/2021 |
SC 13D
| Abingworth LLP reports a 15.4% stake in Jasper Therapeutics, Inc. |
| 09/03/2021 |
SC 13D
| Abingworth LLP reports a 11.9% stake in eFFECTOR Therapeutics, Inc. |
| 05/24/2021 |
SC 13D
| Abingworth LLP reports a 14.6% stake in Vera Therapeutics, Inc. |
| 04/20/2021 |
SC 13D
| Abingworth LLP reports a 7.7% stake in Reneo Pharmaceuticals, Inc.. |
| 03/16/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/08/2021 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 03/08/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/16/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/16/2021 |
SC 13G/A
| Abingworth LLP reports a 0% stake in Personalis, Inc. |
| 10/16/2020 |
SC 13D
| Abingworth LLP reports a 7.7% stake in Spruce Biosciences, Inc. |
| 09/28/2020 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 08/20/2020 |
SC 13G/A
| Abingworth LLP reports a 11.6% stake in Personalis, Inc. |
| 07/31/2020 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/06/2020 |
SC 13D/A
| Abingworth LLP reports a 13.2% stake in Soleno Therapeutics Inc. |
| 02/14/2020 |
SC 13G
| Abingworth LLP reports a 17.4% stake in Personalis, Inc. |
| 02/14/2020 |
SC 13G/A
| Abingworth LLP reports a 2.1% stake in * Chiasma, Inc. |
| 02/10/2020 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 01/17/2020 |
SC 13D/A
| Abingworth LLP reports a 1.9% stake in ArTara Therapeutics, Inc. |
| 11/14/2019 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/09/2019 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 06/17/2019 |
SC 13D/A
| Abingworth LLP reports a 4.9% stake in SIENTRA, INC. |
| 12/27/2018 |
SC 13D
| Abingworth LLP reports a 15.4% stake in Soleno Therapeutics Inc. |
| 05/09/2018 |
SC 13D/A
| Abingworth LLP reports a 8.9% stake in SIENTRA, INC. |
| 02/14/2018 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
|